MADISON, Wis., Aug. 11, 2021 /PRNewswire/ -- Mirus Bio, an innovator in transfection technologies, today announces the launch of the TransIT® VirusGEN® GMP product line. This expansion to the ...

Brooklyn, New York, April 12, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Lentiviral Vector Manufacturing M arket is ...

Germany-based Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities. The companies entered a definitive agreement in May ...

Merck KGaA’s Life Science business in the US and Canada, MilliporeSigma, has entered a definitive agreement to acquire Mirus Bio in a $600m (€500m) deal. The move aims to enhance Merck’s ...

“Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years 1 and will continue to advance, with a projected growth of 30 ...

Mirus Bio specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN ®. These reagents play a critical role in the production of viral vector-based ...

Madison-based Mirus Bio, a manufacturer of transfection regents used in gene therapies, has entered into an agreement to be acquired by MilliporeSigma for $600 million.. MilliporeSigma is the life ...

Concentration of vector stocks can be performed using option A (ultracentrifugation), option B (anion exchange chromatography of lentiviral vector-containing cell culture supernatants using ...

Fred Hutch's Cooperative Center of Excellence in Hematology Vector Production core assists investigators with the design, construction, and/or production of viral vectors (gammaretrovirus, lentivirus, ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Tuesday, 02 January 2024 12:17 GMT 02 January 2024 12:17 GMT. عربي ...